Sysmex Inostics

Our new SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with sensitivity equivalent to our OncoBEAM digital PCR liquid biopsy from across a broader range of genomic regions.OncoBEAM set the gold standard for ctDNA analysis as the most sensitive digital PCR approach available. It has been used to detect subclonal resistance mutations, such as those in ESR1 for breast cancer patients on adjuvant aromatase inhibitor therapy who demonstrate endocrine resistance.With robust detection as low as 0.02% mutant allele frequency (MAF), SafeSEQ ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response. Our cost-effective and industry-leading ultra-sensitive NGS liquid biopsy solutions identify tumor mutations across cancer types for a range of intended uses: Inform therapy selection, Dynamically monitor tumor response, Identify molecular mediators of resistance, Detect minimal residual disease (MRD) at a variant level... More Info Less Info

The SafeSEQ HPV Test is a clinical grade, ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection, including cervical cancer, anal squamous cell carcinoma, and head and neck squamous cell cancer. The SafeSEQ HPV Test detects HPV copies across a high dynamic range of levels and demonstrates a high level of accuracy even when few copies are present, which enables high-resolution molecular monitoring.... More Info Less Info